Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Penelope Flohr"'
Autor:
Johann de Bono, Paul Workman, Aram Oganesian, Harold Keer, Chihche Lin, Ruth Riisnaes, Penelope Flohr, Mateus Crespo, Roberta Ferraldeschi, Joel Picus, Jorge Garcia, Fred Saad, Syed Hussain, Susan Slovin
Supplementary Data from Pharmacodynamic and Clinical Results from a Phase I/II Study of the HSP90 Inhibitor Onalespib in Combination with Abiraterone Acetate in Prostate Cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9277d355e04d8d0cecd899a9da95eec8
https://doi.org/10.1158/1078-0432.22470513.v1
https://doi.org/10.1158/1078-0432.22470513.v1
Autor:
Johann de Bono, Paul Workman, Aram Oganesian, Harold Keer, Chihche Lin, Ruth Riisnaes, Penelope Flohr, Mateus Crespo, Roberta Ferraldeschi, Joel Picus, Jorge Garcia, Fred Saad, Syed Hussain, Susan Slovin
Purpose:Onalespib is a potent, fragment-derived second-generation HSP90 inhibitor with preclinical activity in castration-resistant prostate cancer (CPRC) models. This phase I/II trial evaluated onalespib in combination with abiraterone acetate (AA)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2fc0717438788a30e083724b9d2bf80f
https://doi.org/10.1158/1078-0432.c.6527595.v1
https://doi.org/10.1158/1078-0432.c.6527595.v1
Autor:
Johann S. de Bono, Pasquale Rescigno, Suzanne Carreira, Gemma Fowler, Penelope Flohr, Christina Guo, Mateus Crespo, Andrea Alimonti, Alessandro Vasciaveo, Jian Ning, Bora Gurel, Beshara Sheehan, Jonathan Welti, Semini Sumanasuriya, Alec Paschalis, Lorenzo Buroni, Abdullah Alajati, Ana Ferreira, Susana Miranda, Claudia Bertan, George Seed, Rita de Cássia Pereira, Paul Workman, Rossitza Christova, Diletta Bianchini, Wei Yuan, Matthew Clarke, Andrea Califano, Gunther Boysen, Antje Neeb, Maryou B K Lambros, Adam Sharp, David Dolling, Nina Tunariu, Michael M. Shen, Daniela Brina, Ines Figueiredo, Amanda Swain, Ruth Riisnaes, Jan Rekowski, Caterina Aversa, Martina Troiani, Mariantonietta D'Ambrosio, Veronica Gil
Publikováno v:
Cancer Res
It has been recognized for decades that ERBB signaling is important in prostate cancer, but targeting ERBB receptors as a therapeutic strategy for prostate cancer has been ineffective clinically. However, we show here that membranous HER3 protein is
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::87d5013ff02359d2e158e35ab4c349d9
https://europepmc.org/articles/PMC8932336/
https://europepmc.org/articles/PMC8932336/
Autor:
Rebeca Lozano, David Olmos, Adam Sharp, Penelope Flohr, Pasquale Rescigno, Alison Reid, Casilda Llácer, Ylenia Cendon, Teresa Garcés, Joaquim Mateo, Maria I Pacheco, Elena Castro, Isabel M. Aragón, Shahneen Sandhu, David Lorente, Pedro P. López-Casas, Christophe Massard, Diletta Bianchini, Nuria Romero-Laorden, Paz Nombela, Johann S. de Bono
Publikováno v:
Cancers
r-FHPC. Repositorio Institucional de Producción Científica de la Fundación del Hospital Provincial de Castellón
Banco de España
Cancers, Vol 13, Iss 2334, p 2334 (2021)
Volume 13
Issue 10
Scientia
r-FHPC. Repositorio Institucional de Producción Científica de la Fundación del Hospital Provincial de Castellón
Banco de España
Cancers, Vol 13, Iss 2334, p 2334 (2021)
Volume 13
Issue 10
Scientia
Circulating tumor cell (CTC) enumeration and changes following treatment have been demonstrated to be superior to PSA response in determining mCRPC outcome in patients receiving AR signaling inhibitors but not taxanes. We carried out a pooled analysi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7aab567628c189bece86d7269a3266b7
https://fundanet.fhpcs.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=1350
https://fundanet.fhpcs.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=1350
Autor:
Stephen J. Pettitt, Antje Neeb, Lorna Pope, Jane Goodall, Suzanne Carreira, Joe Baxter, Pasquale Rescigno, Harry Parr, Diletta Bianchini, Claudia Bertan, Stéphane Oudard, Christine Geffriaud-Ricouard, Christopher J. Lord, Sandrine Macé, Oliver Sartor, Ayse Ozatilgan, Rossitza Christova, Gemma Fowler, Maryou B. Lambros, Wei Yuan, Ines Figueiredo, Niven Mehra, Joaquin Mateo, Jan Rekowski, Penelope Flohr, George Seed, Mario A. Eisenberger, Semini Sumanasuriya, Adam Sharp, Mustapha Chadjaa, Johann S. de Bono
Publikováno v:
Scientia
European Urology
European Urology, 80, 2, pp. 243-253
European Urology, 80, 243-253
European Urology
European Urology, 80, 2, pp. 243-253
European Urology, 80, 243-253
Background Better blood tests to elucidate the behaviour of metastatic castration-resistant prostate cancer (mCRPC) are urgently needed to drive therapeutic decisions. Plasma cell-free DNA (cfDNA) comprises normal and circulating tumour DNA (ctDNA).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7bcfbe9a4e19be1664cf6e141fe2f9cb
https://doi.org/10.1016/j.eururo.2021.05.030
https://doi.org/10.1016/j.eururo.2021.05.030
Autor:
Gemma Fowler, Maryou B. Lambros, Pasquale Rescigno, Sandrine Macé, Rossitza Christova, Penelope Flohr, Wei Yuan, Claudia Bertan, Jane Goodall, Lorna Pope, George Seed, Suzanne Carreira, Johann S. de Bono, Semini Sumanasuriya, Harry Parr, Mustapha Chadjaa
Publikováno v:
Cancer Research. 80:LB-270
Background: We, and others, have shown that responses to therapies in metastatic castration-resistant prostate cancer (mCRPC) can be monitored using plasma cell-free DNA (cfDNA), and that this can be both quantitative and qualitative. In this study,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::15a68f54d4856aa3797cd60b03a87328
https://doi.org/10.1158/1538-7445.am2020-lb-270
https://doi.org/10.1158/1538-7445.am2020-lb-270
Autor:
George Seed, Penelope Flohr, Zafeiris Zafeiriou, Berni Ebbs, Mateus Crespo, Nikolas H. Stoecklein, Leon W.M.M. Terstappen, Lucy Hamilton, Claudia Bertan, Susana Miranda, Rita Pereira, Rui P L Neves, Diletta Bianchini, Alan Mackay, Ana Ferreira, Gemma Fowler, Ruth Riisnaes, Joanne Hunt, Maryou B. Lambros, Veronica Gil, Wei Yuan, Deirdre Moloney, Niven Mehra, Adam Sharp, Gunther Boysen, Daniel Nava Rodrigues, Suzanne Carreira, Jane Goodall, Rob Chandler, Ines Figueiredo, Kiki C. Andree, Pasquale Rescigno, Semini Sumanasuriya, Joost F. Swennenhuis, Johann S. de Bono, Mariane Sousa Fontes
Publikováno v:
Clinical cancer research, 24(22), 5635-5644. American Association for Cancer Research Inc.
Clinical Cancer Research, 24, 22, pp. 5635-5644
Clinical Cancer Research, 24, 5635-5644
Clinical Cancer Research, 24, 22, pp. 5635-5644
Clinical Cancer Research, 24, 5635-5644
Purpose: Circulating tumor cells (CTCs) have clinical relevance, but their study has been limited by their low frequency.Experimental Design: We evaluated liquid biopsies by apheresis to increase CTC yield from patients suffering from metastatic pros
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d033184b1472c1356fe71c68340d06cc
https://research.utwente.nl/en/publications/ae159a0d-fd6f-448b-a1d2-237197526150
https://research.utwente.nl/en/publications/ae159a0d-fd6f-448b-a1d2-237197526150
Autor:
Fred Saad, Aram Oganesian, Harold N. Keer, Susan F. Slovin, Ruth Riisnaes, Penelope Flohr, Johann S. de Bono, Mateus Crespo, Roberta Ferraldeschi, Chihche Lin, Joel Picus, Syed A. Hussain, Paul Workman, Jorge A. Garcia
Publikováno v:
Clin Cancer Res
Purpose: Onalespib is a potent, fragment-derived second-generation HSP90 inhibitor with preclinical activity in castration-resistant prostate cancer (CPRC) models. This phase I/II trial evaluated onalespib in combination with abiraterone acetate (AA)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fad9b15974500a0c1e57378b991f4632
https://pubmed.ncbi.nlm.nih.gov/31113841
https://pubmed.ncbi.nlm.nih.gov/31113841
Autor:
Rita Zamarchi, Maarten Joost IJzerman, Beate Zill, Johann S. de Bono, Anne Margreet Sofie Berghuis, Mariane Sousa Fontes, M Tzschaschel, Penelope Flohr, Gemma Fowler, Françoise Farace, Mateus Crespo, Liwen Yang, Sanne de Wit, Rita Lampignano, Alvera Rengel-Puertas, Elisabeth Trapp, Brigitte Rack, Riccardo Vidotto, Emeline Colomba, Marianna Alunni-Fabbroni, Elisabetta Rossi, Hans Neubauer, Mariangela Manicone, Pasquale Rescigno, Leonardus Wendelinus Mathias Marie Terstappen, Kiki C. Andree, Marianne Ouhlen, Tanja Fehm
Publikováno v:
Oncotarget, 9(86), 35705-35716. Impact Journals
Oncotarget, 9(86), 35705-35716. Impact Journals LLC
Oncotarget
Oncotarget, 9(86), 35705-35716. Impact Journals LLC
Oncotarget
The presence of high expressing epithelial cell adhesion molecule (EpCAMhigh) circulating tumor cells (CTC) enumerated by CellSearch® in blood of cancer patients is strongly associated with poor prognosis. This raises the question about the presence
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3bb8a16db1f47625c7515c29b34d629b
https://research.utwente.nl/en/publications/a8a041a9-63c1-4e0f-9c6a-7b3ebe624dc7
https://research.utwente.nl/en/publications/a8a041a9-63c1-4e0f-9c6a-7b3ebe624dc7
Autor:
Ines Figueiredo, Natalee Bales, Daniel Nava Rodrigues, Lukas C. Amler, Ruth Riisnaes, Yibing Yan, Sankar Mohan, Edith Szafer-Glusman, Aurelius Omlin, Gerhardt Attard, Dena Marrinucci, Eric Tucker, Elizabeth Punnoose, Roberta Ferraldeschi, Carmel Pezaro, Shannon L. Werner, Penelope Flohr, Jin Zhu, Johann S. de Bono, Premal Patel, Jessica Louw, Ajay Pandita, Susana Miranda
Publikováno v:
British Journal of Cancer
Background: PTEN gene loss occurs frequently in castration-resistant prostate cancer (CRPC) and may drive progression through activation of the PI3K/AKT pathway. Here, we developed a novel CTC-based assay to determine PTEN status and examined the cor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4d152f8ba4731585213c4bae33571aff
https://doi.org/10.1038/bjc.2015.332
https://doi.org/10.1038/bjc.2015.332